Close Menu

NEW YORK – The latest approval of niraparib (GlaxoSmithKline's Zejula) for heavily pretreated ovarian cancer patients with homologous recombination deficiency (HRD) not only increases the number of patients eligible for the drug, but also adds another biomarker that oncologists can use to help them decide whether to prescribe this PARP inhibitor or another drug. 

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.